Relationship between 5-fluorouracil exposure and outcome in patients receiving continuous venous infusion with or without concomitant radiotherapy

British Journal of Clinical Pharmacology

Volumn 64, Issue 5, 2007, Pages 613-621

  Beneton, Maud ^a   Chapet, Sophie ^a   Blasco, Hélène ^a   Giraudeau, Bruno ^a,b,c   Boisdron Celle, Michèle ^c   Deporte Fety, Régine ^d   Denis, Fabrice ^a   Narcisso, Bérangère ^a   Calais, Gilles ^a,b   Le Guellec, Chantal ^a,b,e  

^a UNIVERSITY HOSPITAL OF TOURS   (France)

^b UNIVERSITÉ DE TOURS   (France)

^c CENTRE PAUL PAPIN   (France)

^d CENTRE RENÉ GAUDUCHEAU   (France)

^e CHU BRETONNEAU   (France)

Author keywords

5 fluorouracil; Drug monitoring; Pharmacokinetics

Indexed keywords

FLUOROURACIL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG EXPOSURE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; MALE; MUCOSA INFLAMMATION; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

CARCINOMA, SQUAMOUS CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 35248830660     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.02951.x     Document Type: Article

References (22)

1. Poplin E, Baker L. Colon cancer: medical therapy. Gastroenterol Clin North Am 1988 17 : 873 86.
2. Milas L, Mason KA, Liao Z, Ang KK. Chemoradiotherapy: emerging treatment improvement strategies. Head Neck 2003 25 : 152 67.
3. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995 332 : 901 6.
4. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 1989 7 : 425 32.
5. Hillcoat BL, McCulloch PB, Figueredo AT, Ehsan MH, Rosenfeld JM. Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion. Br J Cancer 1978 38 : 719 24.
6. Milano G, Roman P, Khater R, Frenay M, Renee N, Namer M. Dose versus pharmacokinetics for predicting tolerance to 5-day continuous infusion of 5-FU. Int J Cancer 1988 41 : 537 41.
7. Santini J, Milano G, Thyss A, Renee N, Viens P, Ayela P, Schneider M, Demard F. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 1989 59 : 287 90.
8. Thyss A, Milano G, Renee N, Vallicioni J, Schneider M, Demard F. Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer. Cancer Chemother Pharmacol 1986 16 : 64 6.
9. Vokes EE, Mick R, Kies MS, Dolan ME, Malone D, Athanasiadis I, Haraf DJ, Kozloff M, Weichselbaum RR, Ratain MJ. Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. J Clin Oncol 1996 14 : 1663 71.
10. Wendt TG, Grabenbauer GG, Rodel CM, Thiel HJ, Aydin H, Rohloff R, Wustrow TP, Iro H, Popella C, Schalhorn A. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998 16 : 1318 24.
11. Fety R, Rolland F, Barberi-Heyob M, Hardouin A, Campion L, Conroy T, Merlin JL, Riviere A, Perrocheau G, Etienne MC, Milano G. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas. Clin Cancer Res 1998 4 : 2039 45.
12. Young AM, Daryanani S, Kerr DJ. Can pharmacokinetic monitoring improve clinical use of fluorouracil? Clin Pharmacokinet 1999 36 : 391 8.
13. Schneider M, Etienne MC, Milano G, Thyss A, Otto J, Dassonville O, Mobayen H, Saudes L, Guillot T, Demard F. Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. J Clin Oncol 1995 13 : 1656 62.
14. Bensadoun RJ, Etienne MC, Dassonville O, Chauvel P, Pivot X, Marcy PY, Prevost B, Coche-Dequeant B, Bourdin S, Vallicioni J, Poissonnet G, Courdi A, Teissier E, Lagrange JL, Thyss A, Santini J, Demard F, Schneider M, Milano G. Concomitant b.i.d. radiotherapy and chemotherapy with cisplatin and 5-fluorouracil in unresectable squamous-cell carcinoma of the pharynx: clinical and pharmacological data of a French multicenter phase II study. Int J Radiat Oncol Biol Phys 1998 42 : 237 45.
15. Milano G, Chamorey AL. Clinical pharmacokinetics of 5-fluorouracil with consideration of chronopharmacokinetics. Chronobiol Int 2002 19 : 177 89.
16. Murphy RF, Balis FM, Poplack DG. Stability of 5-fluorouracil in whole blood and plasma. Clin Chem 1987 33 : 2299 300.
17. Gamelin E, Boisdron-Celle M, Turcant A, Larra F, Allain P, Robert J. Rapid and sensitive high-performance liquid chromatographic analysis of halogenopyrimidines in plasma. J Chromatogr B Biomed Sci Appl 1997 695 : 409 16.
18. Adjei AA, Reid JM, Diasio RB, Sloan JA, Smith DA, Rubin J, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Atherton P, Ames MM, Erlichman C. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. J Clin Oncol 2002 20 : 1683 91.
19. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986 1 : 307 10.
20. Scully C, Epstein J, Sonis S. Oral mucositis: a challenging complication of radiotherapy, chemotherapy, and radiochemotherapy. Part 2: diagnosis and management of mucositis. Head Neck 2004 26 : 77 84.
21. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986 42 : 121 30.
22. Harris BE, Song R, Soong SJ, Diasio RB. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 1990 50 : 197 201.